Xspray Pharma Q3: Exciting Times Ahead

Research Note

2020-11-23

07:20

Redeye reiterates its positive view and Base case of SEK 200 per share following Xspray’s Q3 report. The report did not include any significant surprises. In this note, we briefly comment on financials and highlight important milestones during the period.

LS

Ludvig Svensson

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.